Cardiotoxicity associated with Herceptin (trastuzumab) therapy: A potential mechanism

被引：0
|
作者：
Zuppinger, C
Sawyer, DB
Miller, T
Eppenberger, HM
Suter, TM
机构：
[1] Univ Hosp Bern, CH-3010 Bern, Switzerland
[2] Boston Univ, Dept Med, Myocardial Biol Unit, Boston, MA 02215 USA
[3] Fed Inst Technol ETH, Inst Cell Biol, Zurich, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
10.1016/S0959-8049(02)80300-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
214
引用
收藏
页码：S96 / S96
页数：1
相关论文
共 50 条
  • [21] Clinical trials of Herceptin® (trastuzumab)
    Baselga, J
    EUROPEAN JOURNAL OF CANCER, 2001, 37 : S18 - S24
  • [22] Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin™)
    Fuchs, IB
    Landt, S
    Bueler, H
    Kuehl, U
    Coupland, S
    Kleine-Tebbe, A
    Lichtenegger, W
    Schaller, G
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 (01) : 23 - 28
  • [23] Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
    Holden Eaton
    Kerstin Nina Timm
    Cardio-Oncology, 9
  • [24] Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)
    Ilka B. Fuchs
    Solveig Landt
    Helmut Bueler
    Uwe Kuehl
    Sarah Coupland
    Anke Kleine-Tebbe
    Werner Lichtenegger
    Gerhard Schaller
    Breast Cancer Research and Treatment, 2003, 82 : 23 - 28
  • [25] Direct IHC by Using PolyHRP Labeled Trastuzumab (Herceptin) - A Potential New Companion Diagnostic Test for Herceptin Treatment
    Wang, Li Juan
    Wang, Yihong
    Zhao, Song Q.
    Zhang, Yonghua
    Zhang, Zhiqing
    MODERN PATHOLOGY, 2016, 29 : 524A - 525A
  • [26] Direct IHC by Using PolyHRP Labeled Trastuzumab (Herceptin) - A Potential New Companion Diagnostic Test for Herceptin Treatment
    Wang, Li Juan
    Wang, Yihong
    Zhao, Song Q.
    Zhang, Yonghua
    Zhang, Zhiqing
    LABORATORY INVESTIGATION, 2016, 96 : 524A - 525A
  • [27] Mechanisms of trastuzumab induced cardiotoxicity - is exercise a potential treatment?
    Eaton, Holden
    Timm, Kerstin Nina
    CARDIO-ONCOLOGY, 2023, 9 (01)
  • [28] Concurrent Trastuzumab Use With Radiation Therapy and the Risk for Cardiotoxicity
    Sari, S. Yuce
    Yazici, G.
    Sendur, M. A.
    Altundag, K.
    Gultekin, M.
    Yildiz, F.
    Ozyigit, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E10 - E11
  • [29] Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
    Suter, Thomas M.
    Procter, Marion
    van Veldhuisen, Dirk J.
    Muscholl, Michael
    Bergh, Jonas
    Carlomagno, Chiara
    Perren, Timothy
    Passalacqua, Rodolfo
    Bighin, Claudia
    Klijn, Jan G. M.
    Ageev, Fail T.
    Hitre, Erika
    Groetz, Juergen
    Iwata, Hiroji
    Knap, Malgorzata
    Gnant, Michael
    Muehlbauer, Susanne
    Spence, Alison
    Gelber, Richard D.
    Piccart-Gebhart, Martine J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3859 - 3865
  • [30] Cardiotoxicity associated with the use of trastuzumab in breast cancer patients
    Perik, Patrick J.
    de Korte, Maarten Alexander
    van Veldhuisen, Dirk J.
    Gietema, Jourik A.
    Sleijfer, Dirk T.
    de Vries, Elisabeth G. E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (12) : 1763 - 1771
12345